Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
$7.48
-4.1%
$7.64
$5.47
$11.99
$173.84M-0.2370,710 shs193,339 shs
Compugen Ltd. stock logo
CGEN
Compugen
$1.88
-3.8%
$1.53
$1.13
$2.66
$167.33M2.61400,790 shs678,869 shs
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
$17.70
-5.3%
$18.51
$9.83
$20.98
$166.20M0.6519,365 shs36,119 shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$1.38
-4.8%
$3.37
$1.14
$5.96
$42.77M2.34747,133 shs745,969 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
-0.38%-3.58%+10.80%+35.42%-3.47%
Compugen Ltd. stock logo
CGEN
Compugen
-5.34%+1.56%+41.30%+26.62%+14.71%
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
-6.69%-8.43%+0.70%+46.70%+16.16%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-5.23%-15.70%-62.44%-62.72%-66.12%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
$7.48
-4.1%
$7.64
$5.47
$11.99
$173.84M-0.2370,710 shs193,339 shs
Compugen Ltd. stock logo
CGEN
Compugen
$1.88
-3.8%
$1.53
$1.13
$2.66
$167.33M2.61400,790 shs678,869 shs
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
$17.70
-5.3%
$18.51
$9.83
$20.98
$166.20M0.6519,365 shs36,119 shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$1.38
-4.8%
$3.37
$1.14
$5.96
$42.77M2.34747,133 shs745,969 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
-0.38%-3.58%+10.80%+35.42%-3.47%
Compugen Ltd. stock logo
CGEN
Compugen
-5.34%+1.56%+41.30%+26.62%+14.71%
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
-6.69%-8.43%+0.70%+46.70%+16.16%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-5.23%-15.70%-62.44%-62.72%-66.12%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
2.50
Moderate Buy$20.33174.03% Upside
Compugen Ltd. stock logo
CGEN
Compugen
2.00
Hold$4.00113.33% Upside
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
3.00
Buy$23.0029.32% Upside
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
2.57
Moderate Buy$9.80607.58% Upside

Current Analyst Ratings Breakdown

Latest SKYE, CGEN, FTLF, and ACTU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
Compugen Ltd. stock logo
CGEN
Compugen
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/8/2025
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
10/8/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
10/6/2025
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
10/6/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold$2.00
10/6/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweightNeutral$2.00
9/30/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$20.00
9/27/2025
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Compugen Ltd. stock logo
CGEN
Compugen
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C+)
(Data available from 10/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/AN/AN/AN/A$0.01 per shareN/A
Compugen Ltd. stock logo
CGEN
Compugen
$27.86M6.01N/AN/A$0.62 per share3.02
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
$64.47M2.59$0.90 per share19.77$3.93 per share4.53
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/A$2.25 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
-$27.28MN/A0.00N/AN/AN/A-281.83%N/A
Compugen Ltd. stock logo
CGEN
Compugen
-$14.23M-$0.22N/AN/AN/A-87.45%-34.77%-16.82%11/11/2025 (Estimated)
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
$8.98M$0.8421.1716.17N/A12.63%21.70%13.45%N/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$26.57M-$1.06N/AN/AN/AN/A-76.03%-69.20%N/A

Latest SKYE, CGEN, FTLF, and ACTU Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/11/2025Q3 2025
Compugen Ltd. stock logo
CGEN
Compugen
-$0.09N/AN/AN/A$1.47 millionN/A
8/14/2025Q2 2025
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
-$0.19-$0.30-$0.11-$0.30N/AN/A
8/14/2025Q2 2025
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
$0.18$0.18N/A$0.18$16.17 million$16.13 million
8/7/2025Q2 2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$0.34-$0.44-$0.10-$0.44N/AN/A
8/6/2025Q2 2025
Compugen Ltd. stock logo
CGEN
Compugen
-$0.07-$0.08-$0.01-$0.08$3.95 million$1.26 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/AN/AN/AN/AN/A
Compugen Ltd. stock logo
CGEN
Compugen
N/AN/AN/AN/AN/A
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
N/AN/AN/AN/AN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/A
0.73
0.73
Compugen Ltd. stock logo
CGEN
Compugen
N/A
4.74
4.74
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
0.15
1.71
0.81
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/A
6.09
6.09

Institutional Ownership

CompanyInstitutional Ownership
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
N/A
Compugen Ltd. stock logo
CGEN
Compugen
12.22%
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
2.32%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
21.09%

Insider Ownership

CompanyInsider Ownership
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
69.34%
Compugen Ltd. stock logo
CGEN
Compugen
9.50%
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
61.40%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
4.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Actuate Therapeutics, Inc. stock logo
ACTU
Actuate Therapeutics
1023.24 million7.13 millionN/A
Compugen Ltd. stock logo
CGEN
Compugen
7089.24 million80.76 millionOptionable
FitLife Brands Inc. stock logo
FTLF
FitLife Brands
209.39 million3.63 millionNot Optionable
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
1130.99 million29.59 millionOptionable

Recent News About These Companies

Skye Bioscience (SKYE) was downgraded to a Hold Rating at Craig-Hallum
FY2026 EPS Estimate for Skye Bioscience Lifted by Analyst
Skye Bioscience (NASDAQ:SKYE) Stock Rating Lowered by Craig Hallum
Skye shares crash as obesity drug falls short in key study

New MarketBeat Followers Over Time

Media Sentiment Over Time

Actuate Therapeutics stock logo

Actuate Therapeutics NASDAQ:ACTU

$7.48 -0.32 (-4.10%)
Closing price 04:00 PM Eastern
Extended Trading
$7.41 -0.07 (-0.94%)
As of 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Compugen stock logo

Compugen NASDAQ:CGEN

$1.88 -0.08 (-3.85%)
Closing price 04:00 PM Eastern
Extended Trading
$1.88 +0.00 (+0.05%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

FitLife Brands stock logo

FitLife Brands NASDAQ:FTLF

$17.70 -0.99 (-5.30%)
Closing price 04:00 PM Eastern
Extended Trading
$17.78 +0.09 (+0.48%)
As of 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.

Skye Bioscience stock logo

Skye Bioscience NASDAQ:SKYE

$1.38 -0.07 (-4.83%)
Closing price 04:00 PM Eastern
Extended Trading
$1.38 0.00 (-0.36%)
As of 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.